WCLC 2023 | TRIDENT-1: repotrectinib in ROS1-positive NSCLC

Byoung Chul Cho, MD, PhD, Yonsei University College of Medicine, Seoul, South Korea, outlines the results of a Phase I TRIDENT-1 study (NCT03093116) of repotrectinib, a tyrosine kinase inhibitor (TKI), in locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The primary endpoint of the study was the objective response rate (ORR). Repotrectinib exhibited a significant tumour shrinkage in the majority of patients in cohorts 1 and 4. The treatment continued to demonstrate durable clinical activity during the follow-up of both TKI naïve and pretreated patients. Repotrectinib led to a durable intracranial response and may delay the development of brain lesions in patients with no baseline brain metastases. Dr Cho suggests the results indicate that the early use of repotrectinib can reduce morbidity and mortality due to NSCLC progression in the central nervous system. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.